Kenvue Inc. (NYSE:KVUE - Get Free Report) announced a quarterly dividend on Thursday, October 17th, RTT News reports. Investors of record on Wednesday, November 13th will be given a dividend of 0.205 per share on Wednesday, November 27th. This represents a $0.82 annualized dividend and a yield of 3.77%.
Kenvue has a payout ratio of 67.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Kenvue to earn $1.23 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 66.7%.
Shares of KVUE opened at $21.73 on Thursday. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. Kenvue has a 12 month low of $17.67 and a 12 month high of $23.55. The stock's 50 day moving average is $22.24 and its two-hundred day moving average is $20.19. The firm has a market cap of $41.61 billion, a P/E ratio of 27.86, a PEG ratio of 2.76 and a beta of 1.40.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.28 by $0.04. The company had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. Kenvue's quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the company earned $0.32 earnings per share. Analysts predict that Kenvue will post 1.08 earnings per share for the current fiscal year.
KVUE has been the topic of several research reports. JPMorgan Chase & Co. raised their target price on Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Royal Bank of Canada downgraded Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 target price on the stock. in a research report on Tuesday, September 24th. Jefferies Financial Group assumed coverage on Kenvue in a research report on Tuesday, September 24th. They set a "buy" rating and a $27.00 price objective on the stock. Piper Sandler lifted their price objective on Kenvue from $20.00 to $21.00 and gave the stock a "neutral" rating in a research report on Monday, September 23rd. Finally, UBS Group lifted their price objective on Kenvue from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Kenvue has a consensus rating of "Hold" and an average price target of $22.20.
View Our Latest Report on KVUE
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.